<DOC>
	<DOCNO>NCT02470819</DOCNO>
	<brief_summary>The primary objective examine impact progression-free survival target therapy breast cancer suggest proteomic genomic profiling .</brief_summary>
	<brief_title>Genomic Proteomic Profiling Targets Influenced Treatment Metastatic Breast Cancer</brief_title>
	<detailed_description>To explore impact target therapy breast cancer suggest proteomic genomic profiling use RPMA , target resequencing , IHC analysis , WGS , RNA-seq , Exome sequence progression-free survival . When molecular target identify , patient treat therapy select empirical basis investigator/treating physician individual site follow survival status . Only available , FDA-approved agent use .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Life expectancy &gt; 3 month Diagnosis metastatic breast cancer measurable disease Age great equal 18 year ECOG performance status 01 Able undergo two biopsy obtain tissue first biopsy required second biopsy optional Have fail unable tolerate previous treatment regimen Adequate organ bone marrow function define ANC ≥ 1.5 x 109/L ; Hgb 9 g/dL ; platelet great 100 x 109/L ; creatinine ≤ 1.5 mg/dL ; bilirubin ≤ 2.5 x ULN ; AST ALT ≤ 2.5 x ULN ( ≤ 5 x ULN due underlie liver metastasis ) ; INR ≤ 1.5 x ULN ( except case anticoagulation therapy ) Metastatic lesion accessible biopsy Symptomatic CNS metastasis Previous history another malignancy within 5 year study entry Uncontrolled concurrent illness Known HIV , HBB , and/or HCV infection Pregnant breast feed childbearing potential use adequate birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>